L T Burgers1, A C Vahl2, J L Severens3, A M Wiersema4, P W M Cuypers5, H J M Verhagen6, W K Redekop3. 1. Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: ltburgers@gmail.com. 2. Department of Vascular Surgery, Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands. 3. Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands; Institute of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands. 4. Department of Surgery, Westfriesgasthuis, Hoorn, The Netherlands. 5. Department of Vascular Surgery, Catharina Hospital, Eindhoven, The Netherlands. 6. Department of Vascular Surgery, Erasmus Medical Center, Rotterdam, The Netherlands.
Abstract
OBJECTIVE/ BACKGROUND: The aim of this study was to estimate the lifetime cost-effectiveness of endovascular aneurysm repair (EVAR) versus open surgical repair (OSR) in the Netherlands, based on recently published literature. METHODS: A model was developed to simulate a cohort of individuals (age 72 years, 87% men) with an abdominal aortic aneurysm (AAA) diameter of at least 5.5 cm and considered fit for both repairs. The model consisted of two sub-models that estimated the lifetime cost-effectiveness of EVAR versus OSR: (1) a decision tree for the first 30 post-operative days; and (2) a Markov model for the period thereafter (31 days-30 years). RESULTS: In the base case analysis, EVAR was slightly more effective (4.704 vs. 4.669 quality adjusted life years) and less expensive (€24,483 vs. €25,595) than OSR. Improved effectiveness occurs because EVAR can reduce 30 day mortality risk, as well as the risk of events following the procedure, while lower costs are primarily due to a reduction in length of hospital stay. The cost-effectiveness of EVAR is highly dependent on the price of the EVAR device and the reduction in hospital stay, complications, and 30 day mortality. CONCLUSION: EVAR and OSR can be considered equally effective, while EVAR can be cost saving compared with OSR. EVAR can therefore be considered as a cost-effective solution for patients with AAAs.
OBJECTIVE/ BACKGROUND: The aim of this study was to estimate the lifetime cost-effectiveness of endovascular aneurysm repair (EVAR) versus open surgical repair (OSR) in the Netherlands, based on recently published literature. METHODS: A model was developed to simulate a cohort of individuals (age 72 years, 87% men) with an abdominal aortic aneurysm (AAA) diameter of at least 5.5 cm and considered fit for both repairs. The model consisted of two sub-models that estimated the lifetime cost-effectiveness of EVAR versus OSR: (1) a decision tree for the first 30 post-operative days; and (2) a Markov model for the period thereafter (31 days-30 years). RESULTS: In the base case analysis, EVAR was slightly more effective (4.704 vs. 4.669 quality adjusted life years) and less expensive (€24,483 vs. €25,595) than OSR. Improved effectiveness occurs because EVAR can reduce 30 day mortality risk, as well as the risk of events following the procedure, while lower costs are primarily due to a reduction in length of hospital stay. The cost-effectiveness of EVAR is highly dependent on the price of the EVAR device and the reduction in hospital stay, complications, and 30 day mortality. CONCLUSION: EVAR and OSR can be considered equally effective, while EVAR can be cost saving compared with OSR. EVAR can therefore be considered as a cost-effective solution for patients with AAAs.
Authors: Ramoncito A David; Benjamin S Brooke; Kristine T Hanson; Philip P Goodney; Elizabeth A Genovese; Donald T Baril; Peter Gloviczki; Randall R DeMartino Journal: J Vasc Surg Date: 2017-03-31 Impact factor: 4.268
Authors: Hans Krueger; Sylvia Robinson; Trevor Hancock; Richard Birtwhistle; Jane A Buxton; Bonnie Henry; Jennifer Scarr; John J Spinelli Journal: BMC Health Serv Res Date: 2022-04-26 Impact factor: 2.908
Authors: Carlo Setacci; Pasqualino Sirignano; Vittorio Fineschi; Paola Frati; Giovanna Ricci; Francesco Speziale Journal: Ann Med Surg (Lond) Date: 2017-02-20